Zenotech Laboratories block deals, bulk deals, insider trading and stake changes
BSE: 532039Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 28 Oct 2026. Previous close ₹38.51.
28 Oct: open ₹38.58, high ₹38.89, low ₹37.58
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹231 Cr2,190th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Lossover the last 12 months
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 2.50
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- −4.5%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- −8.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Sep 2026.
- 0.00
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 6,651
Zenotech Laboratories' insiders have 3 trade disclosures on record, the latest on 31 Mar 2022. Its promoter group made no purchase or sale on the market in the 12 months to 28 Oct 2026.
Zenotech Laboratories insider trading
The company's own latest disclosure on record is from Mar 2022.Insider trading, all companies
Mar 2022
- SUN PHARMACEUTICAL INDUSTRIES LIMITED₹5.32 Cr68,86,500 sharesReceived · Promoter · 29 Mar 2022 · disclosed 31 Mar · Inter-se-Transfer · stake 57.56% before, 68.84% after
- DAIICHI SANKYO COMPANY LIMITED₹5.32 Cr68,86,500 sharesGave · Promoter Group · 29 Mar 2022 · Inter-se-Transfer · held 68,86,500 before, holds none after
Jul 2017
- Sun Pharmaceutical Industries Ltd₹86 Cr1,90,00,000 sharesReceived · Promoter · 26 Jul 2017 · disclosed 28 Jul · Rights Issue · held 1,61,28,078 before, holds 3,51,28,078 after
Trades by the company's promoters, directors, key managers, employees and their relatives, as each disclosed them. Value is what the filer stated; the mode is shown where the shares moved off the market.
Zenotech Laboratories stake sales and purchases
All 15 disclosures on record.
Mar 2022
- AcquiredSun Pharmaceutical Industries Ltd11.28% of the company68,86,500 shares29 Mar 2022 · filed as exempt from an open offer
- SoldDaiichi Sankyo Company Ltd · promoter11.28% of the company68,86,500 shares29 Mar 2022 · filed under the 2% rule · Off Market / Inter se transfer
- AcquiredSun Pharmaceutical Industries Ltd · promoter11.28% of the company68,86,500 sharesholds 68.84% after29 Mar 2022 · filed under the 2% rule · Off Market / Inter se transfer
- ProposedSun Pharmaceutical Industries Ltd · promoter11.28% of the company68,86,500 shares26 Mar 2022 · notice before a transfer exempt from an open offer
Jul 2017
- AcquiredHardik B Patel & Ruchit B Patel5.96% of the company36,39,966 sharesholds 5.97% after28 Jul 2017 · filed under the 5% rule · Rights Issue
- AcquiredSun Pharmaceuticals Industries Ltd · promoter31.13% of the company1,90,00,000 sharesholds 57.56% after27 Jul 2017 · filed under the 2% rule · Rights Issue
Mar 2015
- AcquiredSun Pharmacetical · promoter46.84% of the company1,61,27,293 sharesholds 46.84% after24 Mar 2015 · filed under the 5% rule · Scheme Of Arrangement (merger)
Sep 2010
- AcquiredDaiichi Sankyo Company Ltd19.79% of the company68,13,796 sharesholds 19.79% after24 Sep 2010 · filed under the 1997 takeover rules · Open Offer
Aug 2010
- AcquiredDeutsche Securities Mauritius Ltd0.19% of the company65,000 sharesholds 5.10% after5 Aug 2010 · filed under the 1997 takeover rules · Market
Feb 2008
- AcquiredRANBAXY LABORATORIES LIMITED2.21% of the company7,58,851 sharesholds 46.95% after4 Feb 2008
Nov 2007
5 entries
- AcquiredRANBAXY LABORATORIES LIMITED16.00% of the company54,89,536 sharesholds 44.81% after26 Nov 2007
- AcquiredRANBAXY LABORATORIES LIMITED16.00% of the company54,89,536 sharesholds 44.81% after24 Nov 2007
- AcquiredRANBAXY LABORATORIES LIMITED27.35% of the company78,78,906 sharesholds 34.29% after8 Nov 2007
- SoldJAYARAM CHIGURUPATI27.35% of the company78,78,906 sharesholds 10.77% after8 Nov 2007
- AcquiredRANBAXY LABORATORIES LIMITED27.35% of the company78,78,906 sharesholds 34.29% after8 Nov 2007
The 5% rule: an investor discloses on reaching 5% of the company. The 2% rule: a holder of 5% or more discloses each change of 2% or more, including one that takes it below 5%. A transfer exempt from an open offer, the offer to buy from every other shareholder that a large purchase otherwise brings, is disclosed too. Each line shows what its filing states, which can be a smaller change than its rule names.
Zenotech Laboratories block deals and bulk deals
None in the last 12 months, since 29 Oct 2025.Today's bulk and block deals, all companies
ValueValue of a deal. The shares traded times the deal's price.Per cent of the companyPer cent of the company. The shares traded as a percentage of all the company's shares in issue on the day of the deal.
Wednesday 15 Jul 20091 firm · ₹2.38 Cr bought · ₹0 soldNet bought ₹2.38 Cr
- BoughtDEUTSCHE TRUSTEE SERVICES (I) PRIVATE LIMITEDBought 2,22,316 at ₹107.050.65% of the company₹2.38 Cr
Thursday 8 Nov 20074 firms · ₹190 Cr bought · ₹190 Cr soldNet nil
- SoldJAYARAM CHIGURUPATISold 78,78,906 at ₹160.00₹126 Cr
- BoughtRANBAXY LABORATORIES LTDBought 78,78,906 at ₹160.00₹126 Cr
- SoldJAYARAM CHIGURUPATIBlock dealSold 40,00,000 at ₹160.00₹64 Cr
- BoughtRANBAXY LABORATORIES LTDBlock dealBought 40,00,000 at ₹160.00₹64 Cr
A bulk deal is one client trading more than half a per cent of the shares in a day; a block deal is a large trade in the exchange's separate block window, its buyer and its seller each on a line of their own. A firm that bought and sold the shares the same day is on one line, with its net. All 3 deals on record from 4 Jan 2004.